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This article describes methods used to estimate parame-
ters governing long-term survival, or times to other events,
for health economic models. Specifically, the focus is on
methods that combine shorter-term individual-level
survival data from randomized trials with longer-term
external data, thus using the longer-term data to aid
extrapolation of the short-term data. This requires as-
sumptions about how trends in survival for each treatment
arm will continue after the follow-up period of the trial.
Furthermore, using external data requires assumptions
about how survival differs between the populations repre-
sented by the trial and external data. Study reports from
a national health technology assessment program in the
United Kingdom were searched, and the findings were
combined with ‘‘pearl-growing’’ searches of the academic
literature. We categorized the methods that have been
used according to the assumptions they made about how
the hazards of death vary between the external and inter-
nal data and through time, and we discuss the appropri-
ateness of the assumptions in different circumstances.
Modeling choices, parameter estimation, and characteriza-
tion of uncertainty are discussed, and some suggestions
for future research priorities in this area are given. Key
words: internal medicine; detailed methodology; survival
analysis; technology assessment; multiparameter evidence
synthesis. (Med Decis Making 2017;37:377–390)
Models for health economic evaluation typicallyuse observed data from randomized controlled
trials (RCTs) comparing survival (or times to other
events) between competing alternative interven-
tions. However, the choice of intervention will often
affect outcomes over a longer period than the follow-
up time of the RCTs. Policy makers responsible for
making funding decisions will then require esti-
mates of expected survival for a longer period, and
a lifetime horizon is often appropriate.1 If the
observed follow-up time covers a sufficiently large
proportion of the overall survival time, then para-
metric models could be used to extrapolate the
observed trends in the hazard of death for each treat-
ment arm. This is the conventional approach to
long-term survival estimation in health technology
assessments,2 but it assumes that the observed haz-
ard trends will continue into the long term, which
becomes less plausible as the unobserved period in-
creases. The extent of uncertainty surrounding any
extrapolation should also be quantified,1,3 and this
is difficult to determine from short-term data alone
for the same reason.
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In general, long-term survival can be reliably esti-
mated only if there are long-term data, since the
impact of long-term modeling assumptions on the
decision can be substantial.4 Since maximum
follow-up in clinical trials is typically only 1 to 5 y,
some external information is required. This could be
taken from a disease registry, cohort or the general
population, a formally elicited expert belief, or a com-
bination of observed data and informal assumptions.
Most simply, the external ‘‘information’’ could con-
sist of a defensible clinical belief that the risks of death
will continue in a particularway in the long term. The
National Institute for Health and Care Excellence
(NICE) for England and Wales1 recommends that
any extrapolation should be assessed by ‘‘both clini-
cal and biological plausibility of the inferred outcome
as well as its coherence with external data sources,’’
although it does not suggest specific methods to do
this. A number of other national funding agencies
have a similar requirement for long-term outcomes
predictions.5 This article discusses methods that
have been applied to use external data explicitly to
facilitate survival extrapolation, aswell as theirmerits
in different circumstances. Below we describe the
scope and provide the terminology used throughout
the article.
We consider situations where we have both of the
following sources of data.
 RCTs providing estimates of the relative treatment
effect on survival for the patients of interest, with
individual-level survival or censoring times available
for at least 1 treatment arm (either directly or esti-
mated from published Kaplan-Meier curves6).
 Information on longer-term survival from another
source, describing a population with some character-
istics (to be discussed later) in common with the
patients of interest. After some adjustments, these
data can be used to estimate the baseline long-term
survival of the patients of interest. If any treatments
are given, this is unrecorded, so these data give no
information about intervention effects.
We assume the trial data are representative of the
population for which the decision is required. In
practice, however, given the selection criteria of tri-
als, this will not always be strictly true,7–9 which
we will briefly discuss at the end of the article.
The data and extrapolation problem are illustrated
by the hypothetical survival curves in Figure 1. Each
of the 3 ‘‘observed’’ curves are representative samples
of survival from the populations labeled A, B, and C.
The population of interest receiving a control inter-
vention is labeled A, the population of interest
receiving the intervention of interest is labeled B,
and the external population is labeledC. The survivor
functions assumed to generate each data set are
labeled SAðtÞ, SBðtÞ, and SCðtÞ, respectively. We also
define the cumulative hazard HkðtÞ5 log ðSkðtÞÞ
and hazard (or mortality) hkðtÞ5dHkðtÞ=dt for each
group k5A;B;C. The main quantity of interest, the
difference in expected survival between interven-
tions, is
ðtmax
0
SBðtÞ  SAðtÞf gdt;
which is illustrated by the shaded area between the 2
curves. The upper limit tmax is commonly infinite,
giving the lifetime incremental survival.
In the conventional approach,2 SAðtÞ and SCðtÞ are
estimated by parametric models fitted to the A and B
data for t\t1, which are extrapolated to t. t1 to
obtain the incremental survival, without explicitly
considering external long-term validity. Instead, we
discuss approaches that combine the information
onSBðtÞ andSAðtÞ for t\t1, with external information
on SCðtÞ for t\tmax, through assumptions about:
 How survival will differ between the population of
interest and the external population. Specifically,
how SCðtÞ compares to SBðtÞ and SAðtÞ in the interval
t\t1 may give information about how SCðtÞ compares
to the disease population survival after t. t1.
 How observed survival trends under each interven-
tion will continue in the long term, that is, how
Figure 1 Example survival data. The aim is to extrapolate the
incremental expected survival between interventions (B–A) by
using long-term data from an external population (C).
JACKSON AND OTHERS
378  MEDICAL DECISION MAKING/MAY 2017
SBðtÞ and SAðtÞ for t. t1 are related to SBðtÞ and SAðtÞ
for t\t1.
Commonly, instead of using this formula directly to
calculate the incremental survival, SAðtÞ and SBðtÞ
are used to obtain parameters in state-transition or
similar decision-analytic models, which also allow
discounted expected costs and quality-adjusted sur-
vival to be estimated for each competing alternative.
In this article, we focus on how SAðtÞ and SBðtÞ them-
selves can be estimated using external long-term data
and what assumptions are necessary to enable their
estimation.
To find methods that have been used for survival
extrapolation in cost-effectiveness analysis using
external data, we searched the reports of studies car-
ried out under the National Institute of Health
Research Health Technology Assessment Programme
in the United Kingdom and searched academic liter-
ature, focused on health economics and medical
statistics journals, using ‘‘pearl-growing’’ search
methods.10 The exact search strategy, and a broad
classification of the 38 relevant papers that we found,
are given in the online appendix. In this article, we
summarize the methods that have been used, discuss
their appropriateness in different circumstances, and
suggest where further research might be focused.
POTENTIAL EXTERNAL DATA SOURCES
The long-term survivor function for the external
data source SCðtÞ may be estimated from national
administrative data on population survival, disease
registries, cohort studies, or elicited expert belief.
Typical life-tables published by national statistics
authorities provide age, sex, country, year, and
cause-specific annual survival probabilities, which
can be used to estimate lifetime survival for the gen-
eral population. External data may also consist of
cohorts of patients who are similar to the patients of
interest. This could include national or regional reg-
istries (such as cancer registries), or hospital-based
cohorts including all patientswith a particular condi-
tion or receiving a particular treatment, from a partic-
ular period of time. There may even be data from
randomized trials in a similar population with a lon-
ger follow-up. The advantages of registry or cohort
data compared to unselected national population
data are that the patient population may be more rep-
resentative of the target population, and relevant
covariates are more likely to be recorded. However,
theymay not necessarily have follow-up times cover-
ing the whole lifetimes of all participants.
FRAMEWORK FOR SURVIVAL EXTRAPOLATION
USING EXTERNAL DATA
Figure 2 illustrates the choices that need to bemade
when using external data for survival extrapolation.
The structure is based on our categorization of differ-
ent methods used in the literature and our judgment
ofwhen they are appropriate. Each of the next fewsec-
tions of the article discusses a different portion of the
figure in detail. Here, we give a brief overview.
First, researchers should identify if the external
population (C) has the same mortality at all times,
or at least in the long term, as that of the disease pop-
ulation receiving a control intervention (A, top-left
panel) and the disease population receiving the inter-
vention of interest (B, top-right panel). In this case,
the data can then be used directly to estimate each
SkðtÞ without adjustment.
Otherwise, the long-term mortality of populations
A and C (and/or B and C) is assumed to be different
but is systematically similar in such a way that the
external data (C) can be adjusted to estimate the
long-term mortality for the target population with
the disease (A or B). The assumptions that have
been used to do this are represented by the large mid-
dle panel of the figure.
Once any systematic similarity between the inter-
nal and external data has been characterized,
completing the analysis requires a choice of the func-
tional form for each of theSkðtÞ, potential covariate or
subgroup adjustment, parameter estimation, uncer-
tainty, and sensitivity analysis. These issues are dis-
cussed later. Some suggestions for future research
priorities are made, concentrating on how uncer-
tainty about assumptions is represented and the
role of ‘‘soft’’ or elicited information.
DIFFERENCE IN MORTALITY BETWEEN THE
DISEASE AND EXTERNAL POPULATIONS
Disease and External Populations Have the Same
Mortality at All Times
Sometimes, the disease or baseline intervention of
interest is not expected to affect mortality; for exam-
ple, it may affect only quality of life. Then, long-
term survival of the patients of interest can be
assumed to be the same as that of the national popu-
lation of a similar age and sex distribution and taken
directly from the relevant life-table.11,12
SAðtÞ5SCðtÞ for all t:
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This assumption may also hold if the disease or
baseline intervention affectsmortality, but the external
data come from a disease registry or cohort of patients
having the same disease and/or intervention, so that
the survival of the control group in the trial data is
the same as that of the external population.13–19
Figure 2 Framework of model choices for survival extrapolation using external data. Long-term survival S for control and treatment
groups A and B is estimated via assumptions about equivalence of hazards h between populations A, B, and C.
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Disease and External Populations Have the Same
Mortality after Some Time
In other cases, the disease population may have
a higher initial mortality than does the general popu-
lation, but this decreases until at some time (after
t5 tc, say) its death rate converges to the mortality
of that of the general population20–29 (Figure 3, top
left).
hAðtÞ5hBðtÞ5hCðtÞ for all t. tc:
If tc< t1, where t1is the follow-up time of the RCT,
survival for t< tc and t. tc can be taken directly from
the trial data and the life-table data, respectively.Oth-
erwise, if tc. t1, short-term extrapolations from para-
metric models fitted to the individual-level data from
the RCT might be used to estimate the survival prob-
ability between t1 and tc.
25,29,30 If the hazard is
Figure 3 Example hazards for disease and external populations as functions of time, under 4 different assumptions about how the disease
population hazards relate to the external population hazards.
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decreasing in the short term, extrapolating directly
from a parametric model might then lead to hazards
that are lower than those of the age/sex-matched gen-
eral population, which is assumed to be implausible;
therefore, using the life-table data is more appropri-
ate. tc is sometimes interpreted as a ‘‘cure’’ time, so
that all patients who survive this long are assumed
to be ‘‘cured’’ and to have mortality equivalent to
that of the general population.Messori andTrippoli27
also suggested that a compromise between ‘‘cured’’
population survival and ‘‘uncured’’ extrapolated sur-
vival might sometimes be appropriate—see the mod-
els originating from Boag,31 discussed later in this
article, for examples.
Disease and External Populations Have Different
Mortality in the Short and Long Term
If the mortality of patients with the disease is dif-
ferent from that of the population represented by
the external data at all times t\tmax, then extrapola-
tion might be achieved by adjusting the external evi-
dence to make it more representative of the target
population. This requires an assumption that mortal-
ity is systematically different between the popula-
tions in the long term, in a way that can be
determined from the short-term data or informal
beliefs. For example, there may be proportional or
additive hazards for all-cause or cause-specific mor-
tality between the disease and external populations.
These assumptions are discussed in detail later.
DIFFERENCE IN MORTALITY BETWEEN THE
TREATMENT AND CONTROL POPULATIONS
A similar decision should be made about the dif-
ference in mortality between the intervention and
control groups (B andA, respectively). If the interven-
tion is not expected to affectmortality (e.g., if it affects
only quality of life), then SBðtÞ can be assumed to
equal SAðtÞ for all times. If the relative intervention
effect is expected to diminish to null soon after the
end t1 of the trial data, then hBðtÞ can be assumed
to equal hAðtÞ in the long term, and it is sufficient to
estimate hAðtÞ.
SBðtÞ could then be estimated by combining a pub-
lished relative treatment effect from trials,32,33 with
the extrapolated SAðtÞ. The assumptions required to
do this are analogous to those required to extrapolate
differences between the disease and external popula-
tions; typically, the hazard ratio between treatment
groups for all-cause or cause-specific mortality might
be assumed to be constant in perpetuity. Or, if indi-
vidual data are available for the intervention as well
as for the control arm of the trial, SBðtÞ could be pro-
duced independently of SAðtÞ by using external data
and a similar method to that used to estimate SAðtÞ.
Even without external data, SBðtÞ and SAðtÞ are
commonly estimated independently, by parametric
extrapolation.2 This still assumes implicitly that the
short-term differences between the treatment groups
are representative of the long term. Bagust and
Beale30 discuss how knowledge of the treatment’s
mechanism of action might be used to guide long-
term estimation; for example, the effects of a drug
might take some time to achieve after starting treat-
ment and dissipate gradually when treatment stops.
The assumption about how the relative treatment
effect is likely to change as t increases from t1, the
end of trial follow-up, to the time horizon for the deci-
sion model is likely to be an important driver of
which intervention is preferred.34 It is therefore
important to consider uncertainty about this assump-
tion. The fundamental problem is that information
about this effect is available only in the trial data,
not in the long-term data C. NICE1 recommends that
3 alternative scenarios be considered, corresponding
to pessimistic, optimistic, and compromise assump-
tions about the long-term effect of a treatment that is
effective in the short term. For example, expressing
the effect as a hazard ratio hBðtÞ=hAðtÞ, the effect for
t. t1 could be
(a) null, so that hBðtÞ=hAðtÞ5 1 for t. t1;
(b) the same as in the short term, thus hBðtÞ=
hAðtÞ5 exp ðbÞ, assumed constant for all t; or
(c) diminishing in the long term, thus hBðtÞ=hAðtÞ is
increasing from exp ðbÞ to 1.
Beyond informal sensitivity analysis, we did not
find any literature where external information, such
as elicited beliefs or the effects of related treatments
with longer follow-up, was used formally to quantify
future changes in expected treatment effects on
survival.
ADJUSTING EXTERNAL DATA TO REPRESENT
THE POPULATION OF INTEREST
If patients with the disease (under either interven-
tion) and the external population have different
long-term mortality, then one of the following
assumptions might be used to estimate SAðtÞ by
adjusting the long-term external data, and similar
methods might be used to estimate SBðtÞ.
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Proportional Hazards for All-Cause Mortality
between the Disease and External Populations
Several authors35–37 obtained cause-specific mor-
talities hAðtÞ by multiplying those estimated from
life-tables hCðtÞ by a constant hazard ratio obtained
from literature or literature combined with expert
belief.38 These studies assumed proportional
hazards; that is, the hazard ratio between the
disease-specific and general populations is constant
over time (Figure 3, top right).
hAðtÞ5 dhcðtÞ; equivalently SAðtÞ5SCðtÞd:
This is sometimes implemented approximately by
assuming the probabilities of death over a short
period of time (e.g., the cycle length of a state-
transitionmodel) are proportional, instead of the haz-
ards (the instantaneous rates of death, which are not
probabilities39). Instead of taking the hazard ratio
from the literature, Demiris and Sharples40 estimated
it using a joint statistical model for the disease-
specific and external data.
Proportional Cause-Specific Mortality
The proportional hazards assumption can be con-
venient since comparisons of mortality between
groups are often published as hazard ratios. However,
all-cause mortality may not be proportional. For
example, consider the causes of death that contribute
to overall mortality. Let hAðtÞ5hADðtÞ1hAOðtÞ,
where hADðtÞ is the hazard for disease-related mortal-
ity, and hAOðtÞ is the hazard for mortality from all
other causes in population A. Similar notation is
used for populations B and C. Mortality from causes
unrelated to the disease of interest can typically be
assumed to be the same between patients with the
disease and the external population, so that
hAOðtÞ5hBOðtÞ5hCOðtÞ5hOðtÞ:
Mortality for disease-related causes is typically
higher. Suppose the hazards for disease-related mor-
tality are proportional, so that hAðtÞ5ghCDðtÞ1hOðtÞ
(Figure 3, bottom right). This is equivalent only
to an all-cause proportional hazards model
hAðtÞ5 dhCðtÞ5 dðhCDðtÞ1hOðtÞÞ if hCDðtÞ=hOðtÞ is
independent of time. In other words, assuming pro-
portional all-cause hazardswould be valid only if dis-
ease-related mortality were a constant proportion of
the overall mortality in the external population as
time elapses. Benaglia and others41 estimated the
likely extent of bias in various situations when this
assumption is wrongly applied.
To implement a proportional cause-specific haz-
ards model, estimates of hCDðtÞand hOðtÞ can often
be obtained from cause-specific population mortality
rates published by national agencies. As with the all-
cause hazard ratio, the cause-specific hazard ratio g
for disease populations relative to the external popu-
lation might be obtained from the literature or
estimated from short-term comparisons between
internal and external data.42–44 The cause-specific
hazard for the intervention group hBDðtÞcan be esti-
mated similarly bymultiplying hADðtÞ by a published
constant treatment-specific hazard ratio, represent-
ing the effect of the intervention on cause-specific
mortality. This supposes, however, that the causes
of death targeted by the intervention are the same as
the causes that distinguish the disease population
from the general population, which may need to be
investigated.41
In Benaglia and others,41 cause-specific death rates
were published in the population life-tables; thus,
hCDðtÞand hOðtÞcould be obtained easily. However,
they were not published in the disease-specific
individual-level survival data A. To overcome this
and estimate g, since the overall hazard for the dis-
ease population is defined as hAðtÞ5hADðtÞ1hOðtÞ,
a poly-hazard model45 could be applied, which
decomposes the hazard for all-cause mortality as
the sum of cause-specific hazards. Specifically,
a poly-Weibull model was used for the internal data
A,where the cause-specific hazards are bothWeibull,
and Weibull models were simultaneously applied to
the external data. The common other-cause hazard
assumption and proportional cause-specific hazard
assumption then enabled the parameters of all hazard
functions to be estimated through a joint model for
populations A and C. This model implicitly assumes
that the disease has no effect on hazards that have not
been defined as disease-related in the external data,
which cannot be tested unless deaths occurring in
the internal trial patients also have the cause of death
recorded.
A related method, originating from Boag,31
assumes a certain proportion of patients are cured
and estimates a parametric survival function for the
noncured patients. The cure fraction and the param-
eters of the noncured survival function are estimated
jointly from individual data on survival and disease
status. Hisashige and others26 and Maetani and
others46 used this approach to obtain a disease-
related survival curve SADðtÞ for the patients of inter-
est, assuming that the noncured and cured survivor
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functions correspond to disease-related and disease-
unrelated survival, respectively. A disease-unrelated
survivor function SCOðtÞ is obtained from age- and
sex-matched life-table data. The overall extrapolated
survivor function is then calculated as the product of
the disease-related and unrelated survival, assuming
equivalency to the above assumption of proportional
cause-specific and identical other-cause hazards:
SAðtÞ5SADðtÞSAOðtÞ; SAOðtÞ5SCOðtÞ:
Additive Hazards for All-Cause Mortality between
the Disease and External Populations
Instead of a constant risk ratio between internal
and external data sources, some authors47–49 have
assumed that the disease-specific population had
a constant additive excess hazard compared to the
general population (Figure 3, bottom left).
hAðtÞ5hCðtÞ1a:
Under this assumption, it can be shown47 that
logitðSAðtÞ=SCðtÞÞ converges to a linear function as
t increases. Thus, the slope of a linear regression
fitted to the latter part of observed data on
logitðSAðtÞ=SCðtÞÞfor t\t1 gives an estimate of a.
Extrapolations of SAðtÞ for t. t1 can then be calcu-
lated given the estimate of a. Demiris and Sharples40
also investigated additive hazard models within
a Bayesian framework. An advantage of additive haz-
ards is that cause-specific modeling is less important.
If disease-related hazards are additive, so that
hADðtÞ5hCDðtÞ1a and then hAðtÞ5hCDðtÞ1a1
hOðtÞ5hCðtÞ1a, so the additive all-cause hazard
model also holds, and the cause-specific risk differ-
ence a is equal to the all-cause risk difference
hAðtÞ  hCðtÞ. The risk difference (or excess risk) is
straightforward to interpret, and under the additive
hazard model, it is independent of time. A propor-
tional hazards model, however, is multiplicative, so
that the excess risk depends on the baseline risk.
Informally, the disease has a greater effect on people
(such as older people) who are already at a higher risk
of death, which is typical for a chronic disease.
The short-term fit of either the proportional or
additive hazards assumption can be checked from
the data by diagnostic plots2,30 or by embedding in
a model that contains both as special cases, as dis-
cussed by Breslow and Day.50 The assumptions
required to apply either in the long term, however,
are untestable from data.
Other Models for Parameterizing Mortality
Differences between Populations
Other ways of parameterizing difference in
survival between groups include accelerated failure
time models, in which SAðtÞ5SCðdtÞ, so that the
expected survival time in group C is d times
the expected survival time in group A, although we
are unaware of these having been used in the context
of survival extrapolation with external data. Nonpro-
portional, nonadditive hazard models might also be
used where the hazard ratio or excess hazard is a pre-
dictably varying function of time. For example,
Andersson and others51 extrapolated survival of can-
cer patients by combining cancer cohort and life-table
data and modeling the log cumulative excess hazard
for cancer patients as a cubic spline function of log
time,52 assuming a linear trend in the long term.
SURVIVAL MODEL CHOICE WHEN COMBINING
INTERNAL AND EXTERNAL DATA
To complete the estimation and to characterize the
long-term differences between the disease and exter-
nal population survival SAðtÞ and SCðtÞ as well as
between the treatment and control survival SBðtÞ
and SAðtÞ, the form of each survival function needs
to be specified.
Without external data, extrapolation of SAðtÞ and/
orSBðtÞ is typically2 based on a parametric functional
form for each survival curve. With external data,
a parametric function could be specified for SCðtÞ
and fitted to the external data and assumptions
such as proportional hazards used to derive SAðtÞ
and SBðtÞ. To convert annual probabilities of death
published in life-tables to individual-level survival
times, which allows a survivalmodel to be fitted, sev-
eral authors40,41,47,48 have used simulation.
Alternatively, survival extrapolation can be per-
formed semiparametricallywith external data if these
are available up to t5 tmax and if a systematic differ-
ence between the external and internal populations
can be assumed, such as proportional or additive haz-
ards.40,47,48 This has the advantage of avoiding the
risk of misspecifying the baseline survival function.
Fang and others47 used semiparametric models,
which gave plausible estimates where even a 3-
parameter generalized gamma model did not. A
hybrid approach is also possible, using nonparamet-
ric estimates up to some t\t1 and parametric
assumptions to extrapolate,30 although the results
can be sensitive to the arbitrary choice of t.53
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However, if the parametric form fits well, then
fully parametric models can lead to greater precision
in estimates.54 The advantages of parametric and
semiparametric models are combined in a class of
flexible parametric models based on modeling the
log hazard as a spline, or piecewise cubic, function
of log time,52,55 which can adapt to represent survival
arbitrarilywell. Since thesemodels are fully paramet-
ric, they enable extrapolation beyond the times
observed in the data.56 The spline function is defined
to be smooth, and given a particular number of pieces,
results have been shown to be not sensitive to the
choice of where to subdivide the log time axis.55
Therefore, we would expect extrapolations from
this model to be more robust than those from the
‘‘hybrid’’ approach mentioned above. Guyot and
others56 used these models, implemented in the
BUGS software,57 for survival extrapolation using
a combination of trial and long-term external data.
They can also be fitted to single survival data sets
using Stata58 and R.59 Also, unlike the Cox model,
they permit nonproportional hazards to bemodeled52
and extrapolated if necessary.51
The choice between alternative parametric models
for extrapolation is conventionally based on fit to the
short-term data A, B.2 However, as recommended, for
example, in the NICE guidelines,1 long-term plausi-
bility should be considered based on external infor-
mation such as knowledge of the disease, treatment
and trial protocol,30 or related long-term survival
data. External information could simply be used to
inform the choice of model for extrapolation or to
inform particular parameters of a chosen model. A
plausible distribution might be chosen to represent
how the hazard of death is expected to change over
time. For example, the exponential distribution cor-
responds to a constant hazard, which is generally
unrealistic in the long term as the hazard will
increase as people get older. Therefore, even though
data might suggest a constant hazard over the dura-
tion of the RCT, distributions that allow changes in
hazards over time are likely to be more appropriate.
Bagust andBeale30 also discuss how the apparent bet-
ter fit of some parametric models may be an artifact of
between-patient heterogeneity; for example, a Wei-
bull distribution with shape less than 1 could be
explained by a mixture of 2 subpopulations with dif-
ferent constant hazards.
Once the most appropriate model family has been
chosen, its parameters can be estimated; thismight be
done using a combination of disease-specific data A
and external evidence C. For example, Nelson and
others60 used a 2-parameter Gompertz model, which
has an exponentially increasing hazard, to extrapo-
late survival beyond the follow-up of an RCT. The
parameter governing the baseline hazard was
estimated using disease-specific data, and the hazard
‘‘acceleration’’ parameter was estimated from
national population life-tables including older
people.
When long-term data are not available or sparse,
expert belief about long-term survival might be eli-
cited to either choose the parametric form or estimate
particular parameters, as we discuss later.
EXPLAINING POPULATION DIFFERENCES
THROUGH OBSERVED COVARIATES
Under models such as the proportional or additive
hazards specifications described above, the long-
term difference between the populations underlying
the trial and external data is characterized by aparam-
eter such as the all-cause or cause-specific hazard
ratio d or g or risk difference a. This is sufficient to
estimate long-term survival of the trial population if
the model assumptions hold. However, we may also
want to explain this difference in terms of the charac-
teristics of the people represented, for example, to
estimate survival for subgroups of the population
with certain characteristics. This is possible if rele-
vant covariates are recorded in each source of evi-
dence. Nelson and others,60 for example, used
a proportional hazardsmodel inwhich the log hazard
ratio for all-cause mortality is a linear function of the
covariates that distinguish the data sets. The covari-
ate effects were estimated using a semiparametric
model fitted to the long-term external data, to obtain
an expression for survival Sðt; x;bÞ as a function of
covariate values x and covariate effects b. The sur-
vival for group A, SAðtÞ, was estimated for all t by
averaging Sðt;x;bÞ over all covariate values x
observed in the data A. This approach assumes that
the form of the relationship with covariates is the
same between populations A and C, which may not
be true. For example, the relationship of the log haz-
ard of death with age may be linear among younger
people but nonlinear among older people.
It is common to assume that the increase in the haz-
ard of death as a person gets older is fully explained
by his or her increasing age. Thus, survival extrapola-
tions often rely principally onmodeling how the haz-
ard increases with age. Population-based data
commonly cover a wide range of ages and calendar
periods. To exploit this diversity, Nelson and
others60 fitted joint models to a combination of RCT
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and cohort data in an age metric, where the t in SAðtÞ
and SCðtÞ represents age rather than time since diag-
nosis or randomization to treatment. This assumes
that hazards change through time only with increas-
ing age, although the shape of this dependence was
modeled nonparametrically,with no further distribu-
tional assumptions.
Without long-term follow-up data, age effects on
mortality could be estimated from shorter-term data
on individuals with widely varying ages at baseline.
Speight and others13 estimated long-term cancer
survival using registry data in this way. The
(within-person) increase in the risk of death as a per-
son gets older was assumed to equal the risk ratio
between people with different baseline ages.
REPRESENTING UNCERTAINTY AND PARAME-
TER ESTIMATION
It is important to characterize uncertainty in all
model inputs and ‘‘structural’’ model choices3 in
order to determine the uncertainty surrounding the
treatment decision and assess the value of further
research. In the presence of substantial decision
uncertainty, the treatment might be recommended
for use only in research or with otherwise limited
coverage.61 If parameters used to extrapolate survival
are estimated from data, the uncertainty inherent in
estimating them can be handled by probabilistic
methods. For example, in Fang and others,47 uncer-
tainty about the estimation of the hazard increment
bwas propagated through the model to the estimated
survival curve by bootstrapping. Alternatively,
beliefs about b could be represented by a probability
distribution in a standard probabilistic sensitivity
analysis. Uncertainty about the choice of parametric
model can be represented by choosing a sufficiently
flexible model form, such as a spline-based or gener-
alized gamma distribution,56 and, if the level of flex-
ibility required is uncertain and different plausible
models give different results, using model
averaging.62
Bayesian methods are particularly suited to com-
bining evidence from different sources in a model.63
The process involves defining a joint model with
shared parameters representing the aspects that the
different sources of data have in common (e.g., mor-
tality for causes other than the disease of interest)
and different parameters for the parts where they
are expected to differ (e.g., cause-specific mortality).
The posterior distributions of model outputs (such
as incremental expected survival) are estimated
simultaneously conditional on all data, and the
uncertainty about the model inputs is propagated to
the outputs. This approach has been used for combin-
ing data in the context of survival extrapola-
tion,40,41,56,64 as well as in many other decision
modeling contexts.65,66 External aggregate data or
expert beliefs and associated uncertainty can be
included as prior distributions, for example, pub-
lished hazard ratios obtained from meta-analysis.41
A potentially more important uncertainty may
arise in how the differences between the external
and internal data are modeled—in other words,
whether assumptions, such as those set out in this
article, are valid in the long term. This is more prob-
lematic to identify from data; therefore, elicited
beliefs might be used instead.
USING ELICITED BELIEFS IN SURVIVAL
EXTRAPOLATION
Expert elicitation has been used to estimate uncer-
tain quantities in health economic models,67,68
although we are unaware of this approach having
been used in survival extrapolation. Here, we discuss
the potential and challenges.
For example, beliefs about long-term survival
might be elicited directly. Suppose that expert belief
suggested that the 5-y survival probability, Sð5jlÞ,
(assuming t1\ 5) was most likely to be around 0.2
but could be as high as 0.3 or as low as 0.1. Assuming
an exponential survival model, this belief about
Sð5jlÞ5 exp ð5lÞ could be translated to a prior dis-
tribution for the rate l5 log ðSð5jlÞÞ=5. Bayesian
inference could then be used to combine this prior
for long-term survival with the survival data for
t\t1. More complex and realistic parametric models
wouldbemore challenging. For example, in aWeibull
model, eliciting expected survival Sðtja; lÞ5
exp ð  ltaÞ could provide a distribution for lta, but
extra assumptions would be needed to obtain sepa-
rate priors for l and a. To our knowledge, there has
been no investigation of this. Survival estimates
would need to be elicited at multiple time points to
provide information about multiple parameters or to
suggest an appropriate distributional form. Quanti-
ties are most easily elicited if expressed on an inter-
pretable scale.69 Here, that could be the expected
number out of 100 patients who will survive 5 y
and 10 y, but it may be difficult to convert such infor-
mation to priors for parameters. Expressing the eli-
cited information as an artificial extra data set,70
then using standard methods to analyze the original
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data augmented with the additional data, may be
a useful technique to investigate.
If some of the assumptions used to extrapolate are
uncertain, then sensitivity analysis should be per-
formed. The most basic form of sensitivity analysis
is to present results under alternative scenarios and
assumptions; however, scenario analyses can be diffi-
cult to interpret. Instead, the model might be
extended by adding extra parameters representing
these uncertain features, with prior distributions eli-
cited from experts, then observing how the results are
affected.71 For example, to assess the assumption of
a constant hazard ratio between treatment groups,
the treatment effect in the extrapolated period could
be represented by a parametrically decreasing func-
tion of time, and plausible values for the parameter(s)
could be elicited. This allows the associated decision
uncertainty to be formally quantified and ‘‘value of
information’’ methods used to determine whether it
is worth doing further research to assess the assump-
tion.72 Even without elicited information, informal
beliefs could be used to demonstrate, for example,
that the decision about which treatment would be
preferred is robust within a plausible range of
assumptions about some parameter. This might
involve showing that the cumulative incremental
net benefit of the intervention of interest is unlikely
to cross the decision threshold in the period of time
being extrapolated over.73
More research and experience are needed on the
accuracy (and cost) of different methods to elicit
uncertain quantities, ways to combine beliefs of dif-
ferent experts, what quantities should be elicited in
this context, how best to use elicited information in
models, and how the results can be communicated
to decision makers.
SUMMARY AND RESEARCH PRIORITIES
Survival extrapolation given short-term data is
a challenging task, involving prediction of data that
have not been observed. Data on a related long-term
population can often be exploited, but the necessary
assumptions about how the populations differ, and
how short-term trends might continue into the long
term, must be clearly expressed and examined for
plausibility and consistency with external data.
This article reviews typical assumptions that might
be made. However, we may sometimes not be confi-
dent in making any of these assumptions—it may be
unclear whether the external data are relevant or
how to explain differences between the data sets.
The information required to adjust the external pop-
ulation to represent the internal population may not
be available, for example, a marker of disease sever-
ity. In those cases, careful sensitivity analysis and
characterization of uncertainty will be important.
Since long-term assumptions, such as proportional
hazards, are untestable from data, they should be
clearly explained and justified to decision makers.
More experience is needed in situations where nei-
ther proportional nor additive hazards assumptions
are appropriate to distinguish the external and dis-
ease populations, and similarly when the treatment
effect or other key parameters are not constant or oth-
erwise predictable in the long term. Important open
questions concern how ‘‘soft’’ information, such as
formally elicited beliefs or the analyst’s own assumed
distribution for uncertain quantities, can be obtained
and used in modeling. Finally, we assumed that the
trial data are representative of the target population
that will ultimately receive the treatments of interest.
This is not always true given the selection criteria of
trials, although is more plausible for the phase III,
pragmatic trials that typically inform cost-effective-
ness models. Various authors7–9 have suggested
methods and conditions for using external evidence
to adjust the treatment effect from a trial to obtain
the effect in an overlapping but nonidentical popula-
tion. The covariate adjustmentmethodswediscussed
may also be used to explain differences in baseline
survival between populations, if the relevant covari-
ates are recorded.
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